Key result
Insulin resistance (HOMA-IR ≥2.5) was associated with a significantly higher rate of the late catch-up phenomenon after drug-eluting stent implantation compared to no insulin resistance (12.7% vs 2.2%; P=0.048).
Why the study?
Does insulin resistance predict mortality and major adverse cardiac and cerebrovascular events (MACCE) after 1st-generation drug-eluting stent implantation?
Cohort (n=109)
Does insulin resistance predict mortality and major adverse cardiac and cerebrovascular events (MACCE) after 1st-generation drug-eluting stent implantation?
Answers are grounded in this paper and cite their sources.
Insulin resistance may flag higher late catch-up risk after DES; leaves open whether it predicts MACCE or warrants intervention.
BACKGROUND: Percutaneous coronary intervention (PCI) is an effective treatment for patients with ischemic heart disease. In particular, restenosis is suppressed after drug-eluting stent (DES) implantation. However, several problems remain. Previously, we reported neointimal proliferation after DES implantation, which was associated with insulin resistance (IR). The aim of the present study was to clarify whether IR is associated with mortality and major adverse cardiac and cerebrovascular events (MACCE) after 1st-generation DES implantation. METHODS AND RESULTS: We researched the clinical records of 109 patients who had undergone elective PCI and DES implantation between May 2007 and December 2010. We segregated these patients according to the value of the homeostasis model assessment of IR (HOMA-IR) into Group P (n=63; HOMA-IR ≥2.5, positive) and Group N (n=46; HOMA-IR <2.5, negative), and examined the relationship between HOMA-IR and MACCE. The observation period was 7.4±1.6 years. There were no differences between the 2 groups in the occurrence of all-cause death, cardiac death, restenosis, myocardial infarction, stroke, heart failure, or stent thrombosis. However, the late catch-up phenomenon was significantly more common in Group P than in Group N (12.7% vs. 2.2% P=0.048). CONCLUSIONS: IR is a useful predictor of the late catch-up phenomenon after DES implantation, and improvement of IR may help to prevent the phenomenon. (Circ J 2016; 80: 657-662).
No takes yet. Share an insight, caveat, or question.
Komatsu et al. (2016) conducted a cohort in Ischemic heart disease (n=109). Insulin resistance (HOMA-IR ≥2.5) vs. No insulin resistance (HOMA-IR <2.5) was evaluated on Late catch-up phenomenon (p=0.048). Insulin resistance (HOMA-IR ≥2.5) was associated with a significantly higher rate of the late catch-up phenomenon after drug-eluting stent implantation compared to no insulin resistance (12.7% vs 2.2%; P=0.048).
Synapse has enriched 10 related papers. Consider them for comparative context: